Article
Urology & Nephrology
Daniel J. Schaid, Shannon K. McDonnell, Liesel M. FitzGerald, Lissa DeRycke, Zachary Fogarty, Graham G. Giles, Robert J. MacInnis, Melissa C. Southey, Tu Nguyen-Dumont, Geraldine Cancel-Tassin, Oliver Cussenot, Alice S. Whittemore, Weiva Sieh, Nilah Monnier Ioannidis, Chih-Lin Hsieh, Janet L. Stanford, Johanna Schleutker, Cheryl D. Cropp, John Carpten, Josef Hoegel, Rosalind Eeles, Zsofia Kote-Jarai, Michael J. Ackerman, Christopher J. Klein, Diptasri Mandal, Kathleen A. Cooney, Joan E. Bailey-Wilson, Brian Helfand, William J. Catalona, Fredrick Wiklund, Shaun Riska, Saurabh Bahetti, Melissa C. Larson, Lisa Cannon Albright, Craig Teerlink, Jianfeng Xu, William Isaacs, Elaine A. Ostrander, Stephen N. Thibodeau
Summary: This study uses a two-stage design to identify new genetic variants associated with prostate cancer (PCa) in individuals with a family history of the disease or with a more aggressive form of PCa. The research detected 11 known genes associated with PCa and 10 novel genes, most of which are primarily linked to aggressive PCa risk.
Article
Pharmacology & Pharmacy
Daniela A. Rodrigues, Sonia P. Miguel, Jorge Loureiro, Maximiano Ribeiro, Fatima Roque, Paula Coutinho
Summary: The study demonstrated the potential of sodium alginate films with zein nanoparticles loaded with digoxin for buccal drug delivery, aiming to reduce dosing frequency and facilitate quick onset of action. The innovative formulation showed promising properties for drug delivery application and may offer a safer alternative for digoxin administration compared to existing dosage forms on the market.
Article
Oncology
Lei Chen, Yiyi Ji, Ang Li, Bo Liu, Kai Shen, Ruopeng Su, Zehua Ma, Weiwei Zhang, Qi Wang, Yinjie Zhu, Wei Xue
Summary: This study identified fluoxetine, an FDA-approved antidepressant, as a potential therapeutic agent for neuroendocrine prostate cancer (NEPC) through high-throughput drug screening. In vitro and in vivo experiments demonstrated that fluoxetine effectively inhibited neuroendocrine differentiation and cell viability by targeting the AKT pathway. Preclinical tests in NEPC mouse models showed that fluoxetine significantly prolonged overall survival and reduced the risk of tumor distant metastases. These findings repurpose fluoxetine for antitumor application and support its clinical development as a promising therapeutic strategy for NEPC.
FRONTIERS IN ONCOLOGY
(2023)
Editorial Material
Cell Biology
Panagiotis Tsapras, Ioannis P. Nezis
Summary: Macroautophagy/autophagy-related protein Atg8/LC3 plays a crucial role in autophagosome formation and selective degradation of various substrates. A recent study identified several proteins that interact with Atg8a, the Drosophila homolog of Atg8/LC3. Among these proteins, Tak1 and its co-activator Tab2 were found to interact with Atg8a and be subjected to selective autophagic clearance. Additionally, SH3PX1 was shown to interact with Tab2 and play a role in regulating the immune-deficiency (IMD) pathway. These findings provide insights into the regulatory interactions between Tak1-Tab2-SH3PX1 and Atg8a, contributing to the fine-tuning of the IMD pathway.
Article
Medicine, Research & Experimental
Lu-Lu Yu, Bi-Wen Hu, Han-Xue Huang, Bing Yu, Qi Xiao, Qiao-Li Lv, Chen-Hui Luo, Cheng-Xian Guo, Jin-Gao Li, Xiao-Xue Xie, Ji-Ye Yin
Summary: This study identified a genetic variant rs11130424 in the CACNA2D3 gene associated with sensitivity to radiotherapy in patients with nasopharyngeal carcinoma (NPC).
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Ivy Chung, Kun Zhou, Courtney Barrows, Jacqueline Banyard, Arianne Wilson, Nathan Rummel, Atsushi Mizokami, Sudipta Basu, Poulomi Sengupta, Badaruddin Shaikh, Shiladitya Sengupta, Diane R. Bielenberg, Bruce R. Zetter
Summary: The study identified specific compounds that showed preferential cytotoxicity and apoptosis towards metastatic prostate cancer cells, suggesting their potential as effective treatment options for this type of cancer.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Jana Kvizova, Vladimira Pavlickova, Eva Kmonickova, Tomas Ruml, Silvie Rimpelova
Summary: Prostate cancer is often asymptomatic in early stages, leading to late detection and difficult treatment. Research and development of novel therapeutic methods, including combination therapy and potential tools, are crucial for improving treatment outcomes.
Article
Oncology
Duo Liu, Jingjing Zhu, Dan Zhou, Emily G. Nikas, Nikos T. Mitanis, Yanfa Sun, Chong Wu, Nicholas Mancuso, Nancy J. Cox, Liang Wang, Stephen J. Freedland, Christopher A. Haiman, Eric R. Gamazon, Jason B. Nikas, Lang Wu
Summary: The study combines transcriptome-wide association study and validation to identify candidate genes potentially involved in prostate cancer development. Analysis revealed 573 genes associated with prostate cancer risk, including 451 novel genes and 122 previously reported genes.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Cell Biology
Hussain Elhasasna, Raymond Khan, Kalpana K. Bhanumathy, Frederick S. Vizeacoumar, Prachi Walke, Maricris Bautista, Dinesh K. Dahiya, Vincent Maranda, Hardikkumar Patel, Amrutha Balagopal, Nezeka Alli, Anand Krishnan, Andrew Freywald, Franco J. Vizeacoumar
Summary: Neuroendocrine prostate cancer (NEPC) is a highly aggressive form of prostate tumors and often occurs as an adaptive response to androgen deprivation therapy. Overexpression of MYCN oncogene and loss of TP53 and RB1 activities are associated with NEPC. Fludarabine phosphate has been identified as a drug that can selectively inhibit the proliferation of N-MYC overexpressing NEPC cells by inducing reactive oxygen species (ROS).
Article
Biochemistry & Molecular Biology
Isabel Heidegger, Georgios Fotakis, Anne Offermann, Jermaine Goveia, Sophia Daum, Stefan Salcher, Asma Noureen, Hetty Timmer-Bosscha, Georg Schaefer, Annemiek Walenkamp, Sven Perner, Aleksandar Beatovic, Matthieu Moisse, Christina Plattner, Anne Krogsdam, Johannes Haybaeck, Sieghart Sopper, Stefanie Thaler, Markus A. Keller, Helmut Klocker, Zlatko Trajanoski, Dominik Wolf, Andreas Pircher
Summary: This study provides a comprehensive analysis of prostate cancer tumor endothelial cells (TEC) and identifies potential therapeutic targets, specifically the CXCL12/CXCR4 interaction, to interfere with tumor angiogenesis in prostate cancer. Understanding the cell-to-cell communication networks in the tumor microenvironment contributes to the development of new therapeutic approaches for prostate cancer.
Article
Biochemistry & Molecular Biology
Malene Blond Ipsen, Ea Marie Givskov Sorensen, Emil Aagaard Thomsen, Simone Weiss, Jakob Haldrup, Anders Dalby, Johan Palmfeldt, Peter Bross, Martin Rasmussen, Jacob Fredsoe, Soren Klingenberg, Mads R. Jochumsen, Kirsten Bouchelouche, Benedicte Parm Ulhoi, Michael Borre, Jacob Giehm Mikkelsen, Karina Dalsgaard Sorensen
Summary: This study identified new genes associated with olaparib resistance in castration-resistant prostate cancer (CRPC) by performing a genome-wide CRISPR-Cas9 knockout screen. Loss of PARP1, ARH3, YWHAE, or UBR5 was found to cause olaparib resistance, and PARP1 or ARH3 knockout led to cross-resistance to other PARP inhibitors. The study also discovered that reduced autophagy may contribute to PARPi resistance. Low ARH3 expression was identified as an independent predictor of recurrence in prostate cancer patients. These findings enhance our understanding of PARPi response in CRPC and propose a new model of PARPi resistance through decreased autophagy.
Article
Chemistry, Analytical
Yu-Sin You, Yu-Shiang Lin
Summary: Dispensing errors, which are the third leading cause of death in the United States, have prompted the World Health Organization (WHO) to initiate the Medication Without Harm Campaign. This study proposes a novel two-stage induced deep learning (TSIDL) system to efficiently classify similar drugs with diverse packaging, achieving a state-of-the-art classification accuracy of 99.39% and an inference time of only 3.12 ms per image.
Letter
Biochemistry & Molecular Biology
Jin Ji, Rui Chen, Lin Zhao, Yalong Xu, Zhi Cao, Huan Xu, Xi Chen, Xiaolei Shi, Yasheng Zhu, Ji Lyu, Junfeng Jiang, Yue Wang, Tie Zhou, Jingyi He, Xuedong Wei, Jason Boyang Wu, Bo Yang, Fubo Wang
Summary: The study developed an optimized detection strategy for emRNAs and identified novel emRNA signatures for the detection of prostate cancer.
Article
Engineering, Environmental
Qiming Guo, Zhihong Yang, Qun Zhao, Jing Chen, Jie Li, Lijun Chen, Wei Shi, Pinglin An, Guanping Wang, Guangjing Xu
Summary: A pilot-scale two-stage denitrification filter system was developed, using sponge iron and volcanic rock as filter media, for efficient removal of nitrate and chemical phosphorus. The experiment demonstrated that iron ions released from sponge iron filters can achieve simultaneous autotrophic denitrification and chemical P-removal, providing a new approach for nitrogen and phosphorus removal in secondary clarifier effluent.
JOURNAL OF WATER PROCESS ENGINEERING
(2021)
Article
Automation & Control Systems
Zhenhua Huang, Yajun Liu, Choujun Zhan, Chen Lin, Weiwei Cai, Yunwen Chen
Summary: This study introduces a novel group recommendation model with two-stage deep learning, which learns group preferences and optimizes recommendation performance through two sequential stages. Experimental results demonstrate that the proposed model outperforms existing models for group recommendation.
IEEE TRANSACTIONS ON SYSTEMS MAN CYBERNETICS-SYSTEMS
(2022)
Article
Pharmacology & Pharmacy
Baoyuan Zhang, Junfang Lyu, Eun Ju Yang, Yifan Liu, Changjie Wu, Lakhansing Pardeshi, Kaeling Tan, Qiang Chen, Xiaoling Xu, Chu-Xia Deng, Joong Sup Shim
ACTA PHARMACEUTICA SINICA B
(2020)
Article
Multidisciplinary Sciences
Junfang Lyu, Eun Ju Yang, Baoyuan Zhang, Changjie Wu, Lakhansing Pardeshi, Changxiang Shi, Pui Kei Mou, Yifan Liu, Kaeling Tan, Joong Sup Shim
NATURE COMMUNICATIONS
(2020)
Article
Chemistry, Organic
Guanghui Zong, Zhijian Hu, Kwabena Baffour Duah, Lauren E. Andrews, Jianhong Zhou, Sarah O'Keefe, Lucas Whisenhunt, Joong Sup Shim, Yuchun Du, Stephen High, Wei Q. Shi
JOURNAL OF ORGANIC CHEMISTRY
(2020)
Article
Biochemistry & Molecular Biology
Changxiang Shi, Eun Ju Yang, Yifan Liu, Pui Kei Mou, Guowen Ren, Joong Sup Shim
Summary: The study identified BET inhibitors as selective drugs for SMAD4(-/-) CRC cells, inducing growth arrest through the reprogramming of the MYC-p21 axis.
Review
Biotechnology & Applied Microbiology
Changxiang Shi, Eun Ju Yang, Shishi Tao, Guowen Ren, Pui Kei Mou, Joong Sup Shim
Summary: Precision cancer medicine targets defective tumor suppressors through synthetic lethality, which has shown promising results in clinical settings. Large-scale screenings and the discovery of natural products play important roles in identifying synthetic lethal partners of tumor suppressors.
JOURNAL OF ANTIBIOTICS
(2021)
Article
Multidisciplinary Sciences
Ren-Bo Ding, Ping Chen, Barani Kumar Rajendran, Xueying Lyu, Haitao Wang, Jiaolin Bao, Jianming Zeng, Wenhui Hao, Heng Sun, Ada Hang-Heng Wong, Monica Vishnu Valecha, Eun Ju Yang, Sek Man Su, Tak Kan Choi, Shuiming Liu, Kin Iong Chan, Ling-Lin Yang, Jingbo Wu, Kai Miao, Qiang Chen, Joong Sup Shim, Xiaoling Xu, Chu-Xia Deng
Summary: Nasopharyngeal carcinoma (NPC) is a malignant cancer type with high morbidity in Asia, and its current molecular classification is insufficient to predict therapy outcomes. Here the authors explore NPC subtype-specific response to therapy with a pharmacogenomics strategy integrating genomics and drug response of patient-derived organoids. This study provides personalized treatment options for different NPC subtypes based on their molecular characteristics and drug sensitivities, showcasing the application of integrative pharmacogenomics in guiding precision oncology.
NATURE COMMUNICATIONS
(2021)
Article
Biology
Liyun Zhang, Conan Chen, Jie Fu, Brendan Lilley, Cynthia Berlinicke, Baranda Hansen, Ding Ding, Guohua Wang, Tao Wang, Daniel Shou, Ying Ye, Timothy Mulligan, Kevin Emmerich, Meera T. Saxena, Kelsi R. Hall, Abigail Sharrock, Carlene Brandon, Hyejin Park, Tae-In Kam, Valina L. Dawson, Ted M. Dawson, Joong Sup Shim, Justin Hanes, Hongkai Ji, Jun O. Liu, Jiang Qian, David F. Ackerley, Baerbel Rohrer, Donald J. Zack, Jeff S. Mumm
Summary: This study identified potential therapeutic compounds for promoting rod cell survival in RP through cross-species testing in zebrafish and mouse models, with some drugs showing neuroprotective effects across species and suggesting combinatorial drug therapies may provide enhanced therapeutic benefits for RP patients.
Article
Biochemistry & Molecular Biology
Changxiang Shi, Shishi Tao, Guowen Ren, Eun Ju Yang, Xiaodong Shu, Pui Kei Mou, Yifan Liu, Yongjun Dang, Xiaoling Xu, Joong Sup Shim
Summary: SMAD4 loss is frequently observed in colorectal cancer and represents a potential drug target. This study identifies a synthetic lethal interaction between SMAD4 and AURKA, showing that AURKA inhibition selectively inhibits the growth of SMAD4-deficient CRC cells by inducing cell cycle delay and apoptosis. The study also reveals that SMAD4-deficient CRC cells are hyper-dependent on AURKA activity for mitotic exit and survival during SAC hyperactivation.
Review
Biochemistry & Molecular Biology
Yan Zhu, Lukman O. Afolabi, Xiaochun Wan, Joong Sup Shim, Liang Chen
Summary: Neurodegenerative diseases are characterized by the degeneration of the central or peripheral nervous systems and the aggregation of misfolded proteins, leading to cellular dysfunction and brain damage. TRIM proteins play important roles in maintaining protein quality control and clearing misfolded protein aggregates associated with neurodegenerative diseases.
Article
Chemistry, Multidisciplinary
Yunfang Xiong, Ran Ke, Qingyu Zhang, Wenjun Lan, Wanjun Yuan, Karol Nga Ieng Chan, Tom Roussel, Yifan Jiang, Jing Wu, Shuai Liu, Alice Sze Tsai Wong, Joong Sup Shim, Xuanjun Zhang, Ruiyu Xie, Nelson Dusetti, Juan Iovanna, Nagy Habib, Ling Peng, Leo Tsz On Lee
Summary: This study reports the effective modulation of a GPCR for cancer treatment using small activating RNAs (saRNAs) for the first time. The saRNAs promote the expression of MAS1, a GPCR that counteracts cancer cell proliferation and migration. By enhancing MAS1 expression, these saRNAs suppress tumorigenesis and inhibit tumor progression in multiple cancer models. This research not only provides a new strategy for cancer therapy by targeting the renin-angiotensin system, but also offers a new avenue to modulate GPCR signaling through RNA activation.
Article
Oncology
Xuejia Feng, Gui Yang, Litian Zhang, Shishi Tao, Joong Sup Shim, Liang Chen, Qingxia Wu
Summary: This study identified the role of tripartite motif-containing protein 59 (TRIM59) in preventing drug resistance in colorectal cancer (CRC) cells treated with Bortezomib (BTZ). Depletion of TRIM59 enhances endoplasmic reticulum stress and unfolded protein response (UPR) signaling, while also strengthening endoplasmic reticulum-associated degradation (ERAD) and alleviating ROS generation. Knockdown of TRIM59 synergizes with the anti-cancer effect of BTZ both in vitro and in vivo.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Medicine, Research & Experimental
Xiaobo Wang, Jing Huang, Fenglin Liu, Qian Yu, Ruina Wang, Jiaqi Wang, Zewen Zhu, Juan Yu, Jun Hou, Joong Sup Shim, Wei Jiang, Zengxia Li, Yuanyuan Zhang, Yongjun Dang
Summary: Aurora A plays a critical role in G2/M transition and mitosis, making it an attractive target for cancer treatment. However, this study found that the Aurora A inhibitor alisertib upregulated PD-L1 expression, reducing antitumor immunity and paradoxically inhibiting the antitumor effects of alisertib.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Biochemistry & Molecular Biology
Pui Kei Mou, Eun Ju Yang, Changxiang Shi, Guowen Ren, Shishi Tao, Joong Sup Shim
Summary: Recent advances in precision cancer medicine have led to the development of synthetic lethality as a method to target gene combinations in tumors. This approach utilizes the interplay between two genes to selectively kill cancer cells with specific genetic vulnerabilities. By targeting gene mutations that make tumors sensitive to synthetic lethality, researchers have opened up new possibilities in personalized cancer treatment.
EXPERIMENTAL AND MOLECULAR MEDICINE
(2021)
Article
Cell Biology
Hui-Yun Hwang, Joong Sup Shim, Dasol Kim, Ho Jeong Kwon
Summary: This study demonstrates that the antidepressant drug sertraline can induce cellular autophagy by targeting mitochondrial VDAC1, providing a potential new drug candidate for autophagy-related diseases. Additionally, sertraline also suppresses tauopathy by promoting the autophagic degradation of MAPT protein.
Article
Biochemistry & Molecular Biology
Yifan Liu, Eun Ju Yang, Changxiang Shi, Pui Kei Mou, Baoyuan Zhang, Changjie Wu, Junfang Lyu, Joong Sup Shim
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2020)